Chronic myeloid leukemia is increasingly viewed as a chronic illness; most patients have a life expectancy close to that of the general population. Despite progress made using BCR-ABL1 tyrosine kinase inhibitors (TKIs), drug resistance via BCR-ABL1–dependent and BCR-ABL1–independent mechanisms continues to be an issue. BCR-ABL1–dependent resistance is primarily mediated through oncoprotein kinase domain mutations and usually results in overt resistance to TKIs. However, BCR-ABL1–independent resistance in the setting of effective BCR-ABL1 inhibition is recognized as a major contributor to minimal residual disease. Efforts to eradicate persistent leukemic stem cells have focused on combination therapy.
Key points
- •
More than 25% of patients with chronic myeloid leukemia (CML) will switch tyrosine kinase inhibitors (TKIs) during their lifetime owing to resistance or intolerance.
- •
Ponatinib is the only TKI effective against the T315I BCR-ABL1 mutation; its activity derives from its lack of dependence on forming a critical hydrogen bond with residue T315 for high-affinity binding to BCR-ABL1.
- •
Diverse pathways involving growth factors, epigenetic regulators, and apoptotic machinery have been implicated in BCR-ABL1–independent resistance.
- •
CML leukemic stem cells are resistant to TKI therapy and contribute to minimal residual disease. Combination strategies using TKIs and other drugs are an intense focus of investigation.
- •
A minority of patients with CML who achieve sustained deep molecular responses on TKI therapy are able to discontinue treatment without molecular recurrence, entering a state called “treatment-free remission.”
Related posts:
Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms
Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms
Tyrosine Kinase Inhibitors in the Treatment of Eosinophilic Neoplasms and Systemic Mastocytosis
The Development of FLT3 Inhibitors in Acute Myeloid Leukemia
Identification and Targeting of Kinase Alterations in Histiocytic Neoplasms
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
